Efficacy News and Research

RSS

Ligand announces results from melphalan Phase II study on multiple myeloma

Ligand Pharmaceuticals Incorporated announced that results from the Phase II study of its Captisol-enabled, propylene glycol-free (PG-free) Melphalan program were featured this evening in a poster presentation at the combined annual meetings of the Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society for Blood and Marrow Transplantation (ASBMT) in San Diego.

2 Feb 2012

Affinium initiates AFN-1252 Phase 2 trial in acute bacterial skin & skin structure infections

Affinium Pharmaceuticals announced today dosing of the first patient in a multi-center Phase 2 clinical trial evaluating oral AFN-1252 in acute bacterial skin & skin structure infections.

1 Feb 2012

Study demonstrates safety of weight reduction surgery in morbidly obese adolescents

Today, about one in five children in the United States are obese. That means that in just one generation alone the number of obese kids in this country has quadrupled.

1 Feb 2012

NanoViricides files FluCide pre-IND briefing document with the FDA

NanoViricides, Inc. announced today that it has submitted a pre-IND briefing document to the US FDA. This submission provides the required information for the Company's highly effective anti-influenza drug candidate, FluCide, in support of a pre-IND Meeting.

1 Feb 2012

Dana-Farber receives MLSC grant to expand cancer imaging research

The Massachusetts Life Sciences Center has awarded Dana-Farber Cancer Institute a $10 million grant to support the expansion of its pioneering cancer imaging research program.

1 Feb 2012

Study finds sharp increase in BMP use for spinal fusion surgery

The use of bone morphogenetic protein (BMP) for spinal fusion surgery has risen sharply over the past decade, increasing costs with no evidence of improved outcomes, reports study in the February 1 issue of Spine.

1 Feb 2012

NIAID, Aeras partner for Phase II clinical trial of TB vaccine

Aeras announces today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the United States National Institutes of Health (NIH), has joined as a partner for a Phase II proof-of-concept clinical trial of a tuberculosis vaccine candidate jointly developed by Aeras and Dutch biopharmaceutical company Crucell.

1 Feb 2012

Vertex receives FDA approval for Kalydeco to treat rare form of CF

The U.S. Food and Drug Administration today approved Kalydeco (ivacaftor) for the treatment of a rare form of cystic fibrosis (CF) in patients ages 6 years and older who have the specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene.

1 Feb 2012

Exercise training can combat depressive symptoms in patients with chronic illness

Combat feelings of sadness that often accompany chronic illness with a good work-out, say University of Alabama at Birmingham researchers in a study published recently in the Archives of Internal Medicine.

1 Feb 2012

Milestone for Starpharma's drug delivery program

Starpharma Holdings today released animal data which demonstrated that its dendrimer-docetaxel formulation applying Starpharma’s dendrimer technology to the leading chemotherapy drug docetaxel was significantly more efficacious than docetaxel (Taxotere®) in a breast cancer model.

1 Feb 2012

Oral HPV infection more common in men than women: Study

According to a new US study, oral human papillomavirus (HPV) infection is more common among men than women, leading to an increased risk for men of head and neck cancers. HPV causes the majority of cervical cancers, as well as genital and anal - and head and neck cancers.

31 Jan 2012

New research gains increased respect for contraceptive method

Imagine a contraceptive that could, with one or two painless 15-minute non-surgical treatments, provide months of protection from pregnancy. And imagine that the equipment needed were already in physical therapists' offices around the world.

31 Jan 2012

Bioton and Actavis form joint venture

Actavis and Bioton announced today that they have formed a joint venture company for the development and registration of insulins, including analogue insulins.

31 Jan 2012

Takeda returns POSIDUR development and commercialization rights to DURECT

DURECT Corporation today reported that Takeda has given notice that it is returning its development and commercialization rights to POSIDUR in Europe and their other licensed territories.

31 Jan 2012

HSP40/70 linked to hepatitis C infection

Researchers from UCLA's Jonsson Comprehensive Cancer Center have identified a cell-permeable peptide that inhibits a hepatitis C virus protein and blocks viral replication, which can lead to liver cancer and cirrhosis.

31 Jan 2012

UMC to offer ditto device for pediatric patients

Diversionary Therapy Technologies is pleased to announce one of the first U.S. sales of its groundbreaking ditto device, which is clinically proven to lower anxiety and treatment times while improving pediatric patient outcomes. UMC Health System, based in Lubbock, Texas, has purchased and will be offering this revolutionary aid to children at the hospital.

31 Jan 2012

Juventas' JVS-100 Phase I heart failure trial meets primary safety endpoint

Juventas Therapeutics is a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease. The Company's lead product, JVS-100, encodes Stromal cell-Derived Factor 1 (SDF-1) which has been shown to repair damaged tissue through recruitment of circulating stem cells to the site of injury, prevention of ongoing cell death and restoration of blood flow.

31 Jan 2012

End alternative medicine degrees say scientists

A group of more than 400 doctors, medical researchers and scientists are urging universities to close down alternative medicine degrees.

30 Jan 2012

FDA approves Baxter's TISSEEL for general hemostasis in surgery

Baxter International Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved TISSEEL [Fibrin Sealant] to include general hemostasis in surgery when control of bleeding by standard surgical techniques is ineffective or impractical.

From Baxter International Inc. 30 Jan 2012

FDA approves Medtronic DF4 High-Voltage Connector System for ICDs and CRT-Ds

Medtronic, Inc. today announced the U.S. Food and Drug Administration (FDA) approval and launch of the DF4 High-Voltage Connector System, a right ventricular lead and connector used with implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) to detect and accurately treat potentially life-threatening heart rhythms.

From Medtronic 30 Jan 2012